Welcome to our dedicated page for Compass Pathways news (Ticker: CMPS), a resource for investors and traders seeking the latest updates and insights on Compass Pathways stock.
COMPASS Pathways plc reports biotechnology developments centered on COMP360, its proprietary synthetic psilocybin treatment candidate for serious mental health conditions, with treatment-resistant depression as the primary disclosed focus. News commonly covers clinical data, FDA and UK regulatory designations, NDA submission and review activity, and the company's work on delivery models for psychedelic treatment in clinical settings.
Recurring updates also include financial results and business highlights, investor conference participation, collaborations with psychiatry and care-delivery organizations, healthcare provider training initiatives, and equity compensation actions under Nasdaq rules. As an ADR-listed issuer, CMPS news can reflect parent-company operating updates and American Depositary Share-related corporate actions.
COMPASS Pathways (Nasdaq: CMPS) has announced a public offering of 4,000,000 American Depositary Shares (ADSs) at a price of $36.00 each, aiming for total proceeds of $144 million. This offering, which is expected to close around May 4, 2021, will support the company's mission to innovate in mental health care. An additional 600,000 ADSs may be purchased by underwriters. The offering is managed by Cowen, Evercore ISI, and Berenberg, and is compliant with SEC regulations.
COMPASS Pathways plc (Nasdaq: CMPS) has announced a proposed public offering of 4,000,000 American Depositary Shares (ADSs), each representing one ordinary share. The company may grant underwriters a 30-day option to purchase an additional 600,000 ADSs. The offering is subject to market conditions, and there is no guarantee on completion or terms. Joint book-running managers include Cowen, Evercore ISI, and Berenberg, with Cantor Fitzgerald and BTIG as lead managers. A registration statement is pending with the SEC, and the offering is directed only at Qualified Investors in the Relevant States.
COMPASS Pathways (Nasdaq: CMPS) responded positively to a recent study published in the New England Journal of Medicine on April 14, 2021. The study indicates potential efficacy of COMP360 psilocybin compared to escitalopram for major depressive disorder (MDD) involving 59 participants. While the primary measure showed no significant difference, secondary outcomes favored psilocybin, with 70.2% response rates versus 48.0% for escitalopram. Adverse events were similar across both treatments, primarily transient headaches.
COMPASS Pathways plc (Nasdaq: CMPS) announced a corporate update presentation at the 20th Annual Needham Virtual Healthcare Conference on April 15, 2021, at 8:00 am ET. The update will be delivered by CEO George Goldsmith and President Lars Wilde, along with 1:1 investor meetings. A live audio webcast will be accessible via the COMPASS website, with a 30-day replay available afterward. COMPASS focuses on innovative mental health care solutions, particularly through its psilocybin therapy, COMP360, currently in phase IIb clinical trials for treatment-resistant depression.
COMPASS Pathways (Nasdaq: CMPS) has appointed Dr. Wayne J. Riley to its Board of Directors, aiming to enhance its leadership in the mental health sector. Dr. Riley, with over 25 years of experience in healthcare and academia, is currently the President of SUNY Downstate Health Sciences University. His expertise is expected to support COMPASS's innovation in psilocybin therapy for treatment-resistant depression, which has received Breakthrough Therapy designation from the FDA. This appointment comes as COMPASS conducts a phase IIb clinical trial across 22 sites in Europe and North America.
COMPASS Pathways (Nasdaq: CMPS), a mental health care firm, has been granted two new US patents for their synthetic psilocybin formulations aimed at treating major depressive disorder (MDD), including treatment-resistant depression (TRD). Patent No. 10,954,259 was awarded on March 23, 2021, covering crystalline psilocybin and its pharmaceutical formulations. Patent No. 10,947,257 was granted on March 16, 2021, focusing on oral dosage forms of psilocybin. These patents support COMPASS's phase IIb clinical trial for TRD therapy, with anticipated data release in late 2021.
COMPASS Pathways reported progress in its phase IIb clinical trial of COMP360 psilocybin therapy for treatment-resistant depression, with data expected by the end of 2021. The company launched its first Centre of Excellence at Sheppard Pratt in Baltimore to advance mental health care. Financially, COMPASS faced a net loss of $60.3 million in 2020, an increase from $19.6 million in 2019, driven by rising R&D and administrative expenses. Cash reserves stood at $190.3 million by year-end 2020. A conference call is scheduled for March 9, 2021.
COMPASS Pathways (Nasdaq: CMPS) has announced an expansion of its Discovery Center through collaborations with leading scientists from UC San Diego and Medical College of Wisconsin. The new partners, Adam Halberstadt and John McCorvy, will join Jason Wallach in efforts to develop innovative psychedelic compounds targeting mental health issues. This initiative aims to address unmet medical needs and enhance the existing psilocybin therapy model. COMPASS will hold exclusive rights to the new compounds developed during this collaboration.
COMPASS Pathways (Nasdaq: CMPS) has published a paper in Frontiers in Psychiatry detailing its structured therapist training programme for psilocybin therapy. The program aims to ensure consistent quality in psychological support during COMP360 psilocybin therapy, currently in phase IIb clinical trials for treatment-resistant depression. Developed with leading experts, it includes online learning, in-person training, and ongoing mentorship. This initiative addresses previous inconsistencies in training, enhancing the safety and effectiveness of psilocybin therapy.
Summary not available.